FINWIRES · TerminalLIVE
FINWIRES

MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says

By

MannKind (MNKD) is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26 and launch it in August, providing significant upside to its full-year 2026 revenue expectation, Wedbush Securities said in a research note Friday.

Management reiterated its 2026 ReadyFlow net revenue guidance of $110 million to $120 million, assuming about 14% of annual dispenses are generated in Q1 and without any significant contribution from ReadyFlow, the firm noted. Given that assumption, the auto-injector approval could provide strong revenue upside and diversify commercial portfolio, the note added.

Wedbush expects Furoscix revenue growth to resume in Q2, projecting revenue of $22.5 million versus consensus of $24.7 million. With ReadyFlow's contribution, the brokerage expects revenue growth to further accelerate in the second half.

The company's research suggests approximately 65% of healthcare providers expect to increase the use of Furoscix upon ReadyFlow's approval, the brokerage noted.

Wedbush kept an outperform rating on MannKind with a price target of $8 per share.

Price: $4.05, Change: $+0.16, Percent Change: +4.11%

Related Articles

Wire

Business First Bancshares Q2 Earnings, Revenue Rise; Shares Drop After Hours

Business First Bancshares (BFST) reported core Q2 earnings late Thursday of $0.71 per diluted share, up from $0.66 a year earlier.Analysts polled by FactSet expected $0.70.Revenue in the three months ended June 30, expressed as net interest income plus total other income, rose to $91.8 million from $81.5 million.Four analysts expected $91.3 million.The company's shares fell 3.3% in after-hours trading.

$BFST
Wire

RingCentral Q2 Adjusted Earnings, Revenue Rise; FY Guidance Increases

RingCentral (RNG) reported Q2 non-GAAP net income late Thursday of $1.22 per diluted share, up from $1.06 a year earlier.Analysts polled by FactSet expected $1.16.Revenue in the three months ended June 30 rose to $657 million from $620 million a year earlier.Analysts expected $650.5 million.RingCentral expects Q3 non-GAAP EPS of $1.25 to $1.30 on revenue of $664 million to $670 million.Analysts expect EPS of $1.25 on revenue of $663.2 million.The company raised full-year non-GAAP EPS guidance to the range of $4.96 to $5.10 on revenue of $2.635 billion to $2.646 billion. The previous forecast was EPS of $4.85 to $5.01 on revenue of $2.62 billion to $2.64 billion.Analysts expect EPS of $4.92 on revenue of $2.63 billion.RingCentral shares rose 1.2% in after-hours trading.

$RNG
Wire

Robert Half Q2 Net Income, Revenue Fall; Shares Drop After Hours

Robert Half (RHI) reported Q2 net income late Thursday of $0.26 per share, down from $0.41 a year earlier.Analysts polled by FactSet expected $0.26.Revenue in the three months ended June 30 fell to $1.34 billion from $1.37 billion a year earlier.Analysts expected $1.32 billion.The company's shares fell 5.3% in after-hours trading.

$RHI